Hansjakob Furrer
Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study
Boillat-Blanco N, Cavassini M, Günthard H, Furrer H, Clerc O, Aouri M, Bernasconi E, Fulchini R, Rougemont M, Vuichard D, Schöni-Affolter F, Darling K, the Swiss HIV Cohort Study. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. Antivir Ther (Lond) 2014
Jun 25, 2014Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study
Jun 25, 2014Antivir Ther (Lond) 2014
Boillat-Blanco Noémie, Cavassini Matthias, Günthard Huldrych F, Furrer Hansjakob, Clerc Olivier, Aouri Manel, Bernasconi Enos, Fulchini Rosamaria, Rougemont Mathieu, Vuichard Danielle, Schöni-Affolter Franziska, Darling Katharine Ea, the Swiss HIV Cohort Study
Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone
Wang Q, Battegay M, Bucher H, Fehr J, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Young J, Swiss HIV Cohort Study. Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. HIV Clin Trials 2014; 15:92-103.
May 1, 2014Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone
May 1, 2014HIV Clin Trials 2014; 15:92-103
Wang Qing, Battegay Manuel, Bucher Heiner C, Fehr Jan, Furrer Hansjakob, Cavassini Matthias, Calmy Alexandra, Vernazza Pietro, Bernasconi Enos, Young Jim, Swiss HIV Cohort Study
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study
Hasse B, Ledergerber B, Weber R, Di Benedetto C, Fellay J, Calmy A, Battegay M, Hoffmann M, Furrer H, Fehr J, Walker A, Swiss HIV Cohort Study. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014; 58:2363-8.
Feb 10, 2014Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study
Feb 10, 2014Antimicrob Agents Chemother 2014; 58:2363-8
Hasse Barbara, Ledergerber Bruno, Weber Rainer, Di Benedetto Caroline, Fellay Jacques, Calmy Alexandra, Battegay Manuel, Hoffmann Matthias, Furrer Hansjakob, Fehr Jan, Walker A Sarah, Swiss HIV Cohort Study
Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study
Drescher S, Kouyos R, Günthard H, Ledergerber B, Vernazza P, Bernasconi E, Cavassini M, Ambrosioni J, Battegay M, Furrer H, Taffé P, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Yang W, von Wyl V, Swiss HIV Cohort Study. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2013; 58:285-94.
Oct 21, 2013Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study
Oct 21, 2013Clin Infect Dis 2013; 58:285-94
Drescher Sara M, Kouyos Roger D, Günthard Huldrych F, Ledergerber Bruno, Vernazza Pietro, Bernasconi Enos, Cavassini Matthias, Ambrosioni Juan, Battegay Manuel, Furrer Hansjakob, Taffé Patrick, Klimkait Thomas, Aubert Vincent, Shah Cyril, Yerly Sabine, Böni Jürg, Yang Wan-Lin, von Wyl Viktor, Swiss HIV Cohort Study
Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study
von Wyl V, Glass T, Bucher H, Günthard H, Aubert V, Böni J, Bernasconi E, Calmy A, Cavassini M, Furrer H, Nicca D, Yerly S, Klimkait T, Swiss HIV Cohort Study. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. PloS one 2013; 8:e77691.
Oct 16, 2013Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study
Oct 16, 2013PloS one 2013; 8:e77691
von Wyl Viktor, Glass Tracy R, Bucher Heiner C, Günthard Huldrych F, Aubert Vincent, Böni Jürg, Bernasconi Enos, Calmy Alexandra, Cavassini Matthias, Furrer Hansjakob, Nicca Dunja, Yerly Sabine, Klimkait Thomas, Swiss HIV Cohort Study
Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals
Rohrbach J, Rauch A, Furrer H, Bernasconi E, Ambrosioni J, Cavassini M, Vuichard D, Günthard H, Scherrer A, Kovari H, Thormann W, Schmid P, Stickel F, the Swiss HIV Cohort Study. Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals. Antivir Ther (Lond) 2013
Sep 13, 2013Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals
Sep 13, 2013Antivir Ther (Lond) 2013
Rohrbach Janine, Rauch Andri, Furrer Hansjakob, Bernasconi Enos, Ambrosioni Juan, Cavassini Matthias, Vuichard Danielle, Günthard Huldrych F, Scherrer Alexandra, Kovari Helen, Thormann Wolfgang, Schmid Patrick, Stickel Felix, the Swiss HIV Cohort Study
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients
Beerenwinkel N, Günthard H, Cellerai C, Klimkait T, Böni J, Yerly S, Bernasconi E, Vernazza P, Cavassini M, Hirschel B, Battegay M, Furrer H, von Wyl V, Knupfer P, Schuhmacher H, Montazeri H, Swiss HIV Cohort Study. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. PLoS Comput Biol 2013; 9:e1003203.
Aug 29, 2013The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients
Aug 29, 2013PLoS Comput Biol 2013; 9:e1003203
Beerenwinkel Niko, Günthard Huldrych F, Cellerai Cristina, Klimkait Thomas, Böni Jürg, Yerly Sabine, Bernasconi Enos, Vernazza Pietro, Cavassini Matthias, Hirschel Bernard, Battegay Manuel, Furrer Hansjakob, von Wyl Viktor, Knupfer Patrick, Schuhmacher Heike, Montazeri Hesam, Swiss HIV Cohort Study
Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study
Wandeler G, Rauch A, Furrer H, Egger M, Calmy A, Battegay M, Schmid P, Kovari H, Cavassini M, Bernasconi E, Bihl F, Gsponer T, Swiss HIV Cohort Study. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis 2013; 208:1454-8.
Jul 30, 2013Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study
Jul 30, 2013J Infect Dis 2013; 208:1454-8
Wandeler Gilles, Rauch Andri, Furrer Hansjakob, Egger Matthias, Calmy Alexandra, Battegay Manuel, Schmid Patrick, Kovari Helen, Cavassini Matthias, Bernasconi Enos, Bihl Florian, Gsponer Thomas, Swiss HIV Cohort Study
Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PloS one 2013; 8
Jul 25, 2013Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
Jul 25, 2013PloS one 2013; 8
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, the Swiss HIV Cohort Study (SHCS)
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013; 208:1102-12.
Jul 11, 2013Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
Jul 11, 2013J Infect Dis 2013; 208:1102-12
Metzner Karin J, Aubert Vincent, Furrer Hansjakob, Battegay Manuel, Vernazza Pietro, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Weber Rainer, Günthard Huldrych F, Klimkait Thomas, Yerly Sabine, Böni Jürg, Scherrer Alexandra U, Preiswerk Benjamin, Joos Beda, von Wyl Viktor, Leemann Christine, Rieder Philip, Braun Dominique, Grube Christina, Kuster Herbert, Swiss HIV Cohort Study
HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis
Fenner L, Cavassini M, Calmy A, Dolina M, Frei R, Janssens J, Borrell S, Stucki D, Schrenzel J, Böttger E, Gagneux S, Bernasconi E, Hoffmann M, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, Helbling P, Fehr J, Gsponer T, Rieder H, Zwahlen M, Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups. HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis. PLoS Genet 2013; 9:e1003318.
Mar 7, 2013HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis
Mar 7, 2013PLoS Genet 2013; 9:e1003318
Fenner Lukas, Cavassini Matthias, Calmy Alexandra, Dolina Marisa, Frei Reno, Janssens Jean-Paul, Borrell Sonia, Stucki David, Schrenzel Jacques, Böttger Erik C, Gagneux Sebastien, Bernasconi Enos, Hoffmann Matthias, Egger Matthias, Bodmer Thomas, Furrer Hansjakob, Ballif Marie, Battegay Manuel, Helbling Peter, Fehr Jan, Gsponer Thomas, Rieder Hans L, Zwahlen Marcel, Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PloS one 2012; 7:e50307.
Nov 26, 2012Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
Nov 26, 2012PloS one 2012; 7:e50307
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, Swiss HIV Cohort Study (SHCS)
The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study
Wang Q, Fux C, Bucher H, Stoeckle M, Furrer H, Weber R, Hirschel B, Vernazza P, Cavassini M, Bernasconi E, Young J, Swiss HIV Cohort Study. The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study. Antivir Ther (Lond) 2012; 18:337-44.
Sep 12, 2012The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study
Sep 12, 2012Antivir Ther (Lond) 2012; 18:337-44
Wang Qing, Fux Christoph, Bucher Heiner C, Stoeckle Marcel, Furrer Hansjakob, Weber Rainer, Hirschel Bernard, Vernazza Pietro, Cavassini Matthias, Bernasconi Enos, Young Jim, Swiss HIV Cohort Study
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic
Wandeler G, Rauch A, Furrer H, Bernasconi E, Stöckle M, Calmy A, Clerc O, Günthard H, Bregenzer A, Gsponer T, Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55:1408-16.
Aug 14, 2012Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic
Aug 14, 2012Clin Infect Dis 2012; 55:1408-16
Wandeler Gilles, Rauch Andri, Furrer Hansjakob, Bernasconi Enos, Stöckle Marcel, Calmy Alexandra, Clerc Olivier, Günthard Huldrych F, Bregenzer Andrea, Gsponer Thomas, Swiss HIV Cohort Study
Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes
Elzi L, Battegay M, Weber R, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Furrer H, Erb S, for the Swiss HIV Cohort Study. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. Arch Intern Med 2012:1-9.
Aug 13, 2012Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes
Aug 13, 2012Arch Intern Med 2012:1-9
Elzi Luigia, Battegay Manuel, Weber Rainer, Bernasconi Enos, Vernazza Pietro, Hirschel Bernard, Cavassini Matthias, Ledergerber Bruno, Furrer Hansjakob, Erb Stefan, for the Swiss HIV Cohort Study
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Cellerai C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PloS one 2012; 7:e37983.
Jun 18, 2012Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
Jun 18, 2012PloS one 2012; 7:e37983
Scherrer Alexandra U, Günthard Huldrych F, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Cellerai Cristina, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study
Bucher H, Battegay M, Furrer H, Weber R, Hirschel B, Vernazza P, Cavassini M, Wang Q, Magenta L, Glass T, Richter W, Bernasconi E. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012; 60:135-42.
Jun 1, 2012Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study
Jun 1, 2012J Acquir Immune Defic Syndr 2012; 60:135-42
Bucher Heiner C, Battegay Manuel, Furrer Hansjakob, Weber Rainer, Hirschel Bernard, Vernazza Pietro, Cavassini Matthias, Wang Qing, Magenta Lorenzo, Glass Tracy R, Richter Werner, Bernasconi Enos
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
Young J, Bucher H, Battegay M, Weber R, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Furrer H, Fux C, Schäfer J, the Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567-575.
Mar 13, 2012Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
Mar 13, 2012AIDS 2012; 26:567-575
Young Jim, Bucher Heiner C, Battegay Manuel, Weber Rainer, Cavassini Matthias, Calmy Alexandra, Vernazza Pietro, Bernasconi Enos, Furrer Hansjakob, Fux Christoph A, Schäfer Juliane, the Swiss HIV Cohort Study
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study
Staehelin C, Furrer H, Bernasconi E, Schmid P, Cavassini M, Elzi L, Weber R, Calmy A, Keiser O, Swiss HIV Cohort Study. Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012; 59:79-85.
Jan 1, 2012Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study
Jan 1, 2012J Acquir Immune Defic Syndr 2012; 59:79-85
Staehelin Cornelia, Furrer Hansjakob, Bernasconi Enos, Schmid Patrick, Cavassini Matthias, Elzi Luigia, Weber Rainer, Calmy Alexandra, Keiser Olivia, Swiss HIV Cohort Study
A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA
Wandeler G, Furrer H, Vernazza P, Clerc O, Battegay M, Bernasconi E, Günthard H, Hirschel B, Keiser O, Swiss HIV Cohort Study. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PloS one 2011; 6:e27903.
Dec 20, 2011A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA
Dec 20, 2011PloS one 2011; 6:e27903
Wandeler Gilles, Furrer Hansjakob, Vernazza Pietro, Clerc Olivier, Battegay Manuel, Bernasconi Enos, Günthard Huldrych F, Hirschel Bernard, Keiser Olivia, Swiss HIV Cohort Study